Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/06/008844
CTRI/2017/06/008844
Completed
未知

Follow up clinical study to evaluate persistence of immunogenicity (antivi IgG antibody) post vaccination of single dose of vi conjugate typhoid vaccine (peda Typh) given to infants and children in 2007 - TCV

Biomed private limited0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Biomed private limited
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Biomed private limited

Eligibility Criteria

Inclusion Criteria

  • •1\. healthy subject
  • •2\. only those volunteers will be enrolled who received peda typh vaccine in year 2007

Exclusion Criteria

  • •1\.unhealthy volunteers
  • •2\. volunteers who were not received peda typh dose in year 2007

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
A study to evaluate clinical factors responsible for functional and cognitive outcome after stroke in ischemic stroke patients.
CTRI/2020/01/022783Kasturba Medical College Manipal
Completed
Not Applicable
Prospective observational study on the clinical relevance of the combined PET / MR examination in pediatric oncologyC00-C97Malignant neoplasms
DRKS00024123niversitätsklinikum Tübingen74
Recruiting
Not Applicable
A prospective study to evaluate long-term clinical outcomes of the GTS cementless femoral stemJoint wearOsteoarthritis10023213
NL-OMON55672Zimmer Biomet23
Completed
Not Applicable
Prospective, longitudinal cohort study of follow-up in patients with COVID-19 infection and requiring inpatient treatment for respiratory diseaseCOVID-19
DRKS00027106niversitätsklinikum der RWTH Aachen278
Active, not recruiting
Phase 1
Extension study for the follow up of patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulated and blinded controlled treatment to evaluate safety and efficacy of a drug administered (etamsilato) via a needle in the eye. Clinical trial code OFT-ETAMSILATO -4.2.1
EUCTR2015-001812-36-ESDr. Pedro Cuevas Sanchez (Investigacion Independiente)44